Scholarlink

Background <p>Preoperative anemia (PA) has been recognized as a potential prognostic biomarker in various urologic malignancies; however, its significance in patients with bladder carcinoma undergoing radical cystectomy (RC) remains insufficiently defined. This study aimed to evaluate the prognostic value of PA on survival and recurrence outcomes in patients treated with RC.</p> Methods <p>A retrospective analysis was conducted on 299 patients who underwent RC for nonmetastatic bladder cancer between 2015 and 2018. Patients were stratified into anemia and nonanemia groups based on age- and sex-adjusted hemoglobin thresholds. Clinicopathologic characteristics were compared. The impact of PA on overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) was assessed by using Kaplan–Meier analysis and Cox proportional hazards models.</p> Results <p>Preoperative anemia was present in 159 patients (53.2%) and was significantly associated with adverse clinicopathologic factors, including higher tumor stage, higher tumor grade, lymphovascular invasion, hydronephrosis, hypoalbuminemia, and thrombocytosis (all <i>p</i> &lt; 0.05). In univariate analyses, PA was associated with worse OS (hazard ratio [HR] 2.199, <i>p</i> &lt; 0.001), CSS (HR 2.345, <i>p</i> &lt; 0.001), and RFS (HR 1.955, <i>p</i> = 0.005). Multivariate analyses confirmed PA as an independent predictor of OS (HR 1.455, <i>p</i> = 0.022), CSS (HR 1.566, <i>p</i> = 0.010), and RFS (HR 1.622, <i>p</i> = 0.044). Kaplan–Meier curves demonstrated significantly poorer survival outcomes across all endpoints in anemic patients. The 5-year CSS estimate was 35.8% in patients with PA.</p> Conclusions <p>Preoperative anemia is an independent adverse prognostic factor for survival and recurrence in patients with bladder carcinoma treated with radical cystectomy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic Value of Preoperative Anemia on Survival and Recurrence in Patients with Bladder Carcinoma Treated by Radical Cystectomy

  • 期刊论文

  • 发表日期：

    2026年1月12日

查看全文
  • Milan Sretenovic,
  • Uros Bumbasirevic,
  • Nebojsa Bojanic,
  • Otas Durutovic,
  • Aleksandar Janicic,
  • Boris Kajmakovic,
  • Milos Petrovic,
  • Petar Bulat,
  • Sandra Sipetic Grujicic,
  • Bogomir Milojevic

摘要

Background

Preoperative anemia (PA) has been recognized as a potential prognostic biomarker in various urologic malignancies; however, its significance in patients with bladder carcinoma undergoing radical cystectomy (RC) remains insufficiently defined. This study aimed to evaluate the prognostic value of PA on survival and recurrence outcomes in patients treated with RC.

Methods

A retrospective analysis was conducted on 299 patients who underwent RC for nonmetastatic bladder cancer between 2015 and 2018. Patients were stratified into anemia and nonanemia groups based on age- and sex-adjusted hemoglobin thresholds. Clinicopathologic characteristics were compared. The impact of PA on overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) was assessed by using Kaplan–Meier analysis and Cox proportional hazards models.

Results

Preoperative anemia was present in 159 patients (53.2%) and was significantly associated with adverse clinicopathologic factors, including higher tumor stage, higher tumor grade, lymphovascular invasion, hydronephrosis, hypoalbuminemia, and thrombocytosis (all p < 0.05). In univariate analyses, PA was associated with worse OS (hazard ratio [HR] 2.199, p < 0.001), CSS (HR 2.345, p < 0.001), and RFS (HR 1.955, p = 0.005). Multivariate analyses confirmed PA as an independent predictor of OS (HR 1.455, p = 0.022), CSS (HR 1.566, p = 0.010), and RFS (HR 1.622, p = 0.044). Kaplan–Meier curves demonstrated significantly poorer survival outcomes across all endpoints in anemic patients. The 5-year CSS estimate was 35.8% in patients with PA.

Conclusions

Preoperative anemia is an independent adverse prognostic factor for survival and recurrence in patients with bladder carcinoma treated with radical cystectomy.